Publication

Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2–positive primary breast cancer: analysis from the altto phase iii randomized trial

Sonnenblick, Amir
; 
Agbor-Tarh, Dominique
; 
Bradbury, Ian
; 
Di Cosimo, Serena
; 
Azim, Hatem A.
; 
Fumagalli, Debora
; 
Sarp, Severine
; 
Wolff, Antonio C.
; 
Andersson, Michael
; 
Kroep, Judith
... show 10 more
Identifiers
http://hdl.handle.net/10379/13984
 https://doi.org/10.13025/26760
Publication Date
2017-05-01
Keywords
mediates trastuzumab resistance, adjuvant chemotherapy, her2+breast cancer, cell-growth, survival, activation, stat3, women, associations, population
Type
Article
Downloads
Show all metadata
Citation
Sonnenblick, Amir; Agbor-Tarh, Dominique; Bradbury, Ian; Di Cosimo, Serena; Azim, Hatem A. Fumagalli, Debora; Sarp, Severine; Wolff, Antonio C.; Andersson, Michael; Kroep, Judith; Cufer, Tanja; Simon, Sergio D.; Salman, Pamela; Toi, Masakazu; Harris, Lyndsay; Gralow, Julie; Keane, Maccon; Moreno-Aspitia, Alvaro; Piccart-Gebhart, Martine; de Azambuja, Evandro (2017). Impact of diabetes, insulin, and metformin use on the outcome of patients with human epidermal growth factor receptor 2–positive primary breast cancer: analysis from the altto phase iii randomized trial. Journal of Clinical Oncology 35 (13),
Abstract
Funder
Publisher
American Society of Clinical Oncology (ASCO)
Publisher DOI
Rights
Attribution-NonCommercial-NoDerivs 3.0 Ireland
cbn
Collections
Externally hosted open access publications with University of Galway authors (2)